Edgewise (EWTX) CFO Michael Nofi Receives Option Award

What Happened

• Michael Nofi, Chief Financial Officer of Edgewise Therapeutics (EWTX), was granted 48,750 stock options on 2026-08-12. The amended Form 4 corrects the exercise price to $43.56 (previously reported as $0.00 in error). The aggregate exercise price to acquire all underlying shares would be $48,750 × $43.56 = $2,123,550. This is an option award (derivative grant), not an open-market purchase or sale.

Key Details

• Transaction date: August 12, 2026 (reported via amended filing on August 17, 2026).
• Transaction type: Award/Grant of derivative securities (options).
• Quantity: 48,750 options.
• Exercise (strike) price: $43.56 per share (corrected from a clerical $0.00).
• Aggregate exercise price (if exercised in full): $2,123,550.
• Vesting: 1/48th of the option shares vest each month beginning September 12, 2026, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in this filing.
• Filing status: This is an AMENDED Form 4 correcting the exercise price error in the originally reported grant.

Context

• Because the option strike equals the fair market value on the grant date (as stated), there was no immediate intrinsic gain at grant. The options vest monthly over 48 months, so they are service‑conditioned compensation rather than an immediate market buy or sale. This filing corrects a clerical error in the originally reported exercise price; it does not indicate any immediate sale of shares.